Skip to main content

Inotuzumab Ozogamicin Approved for Pediatric Patients with Acute Lymphoblastic Leukemia

The FDA has granted approval to inotuzumab ozogamicin (Besponsa™, Pfizer) for pediatric patients one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).   Why it matters: "Among adult patients with relapsed or refractory B-ALL, the use of inotuzumab ozogamicin has led to improved outcomes as compared to those treated with chemotherapy alone," said Tristan Knight, MD, FRCPC, an Oncology Data Advisor Editorial Board Member and Clinical...

Continue reading

Bosutinib Approved for Pediatric Patients With Chronic Myelogenous Leukemia

The FDA has approved bosutinib (Bosulif®, Pfizer) for treatment of pediatric patients with newly diagnosed or resistant/intolerant to prior therapy chronic phase (CP) Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia (CML). In addition, the FDA has approved a new capsule dosage available as 50 mg and 100 mg.   Why it matters: "Bosutinib is a tyrosine kinase inhibitor (TKI), approved for adults with Ph-positive CML," wrote Edoardo Pennesi, a Doctoral Researcher at Princes Ma...

Continue reading